Clinical Scorecard: Addressing Adverse Effects of Antibody-Drug Conjugates in Breast Cancer Treatment

At a Glance

Key Highlights

• ADCs have transformed breast cancer therapeutics by delivering chemotherapy directly to cancer cells.
• Management of treatment-related toxicities is critical for improving patient outcomes.
• Distinct toxicity signatures are associated with different ADCs based on payload, linker stability, and antigen expression.
• Proposed algorithms for managing organ-specific adverse events.
• Need for multidisciplinary coordination and early recognition of toxicities.

Guideline-Based Recommendations

Diagnosis

• Utilize clinical-trial and real-world data to assess toxicity profiles of ADCs.

Management

• Implement organ-system–based frameworks for anticipating and managing toxicities.

Monitoring & Follow-up

• Conduct precise toxicity surveillance as ADCs are introduced earlier in treatment.

Risks

• Recognize complex toxicity patterns that differ from conventional chemotherapy.

Patient & Prescribing Data

Patients receiving trastuzumab deruxtecan, sacituzumab govitecan, and datopotamab deruxtecan.

Real-world implementation reveals multifaceted toxicities requiring tailored management strategies.

Clinical Best Practices

• Early recognition of adverse events to enhance treatment safety.
• System-specific mitigation strategies to improve adherence to therapy.
• Integration of evidence from clinical trials and real-world experiences in practice.

Related Resources & Content

• Clinical Trials and Guidelines on ADC Safety